文献速递临床微生物质量管理与危急值

Vitek 2美罗培南-韦博巴坦对肠杆菌目和铜绿假单胞菌药敏的多中心临床评估

Multicenter Clinical Evaluation of Vitek 2 Meropenem-Vaborbactam for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa.
PubMed 文献 · J Clin Microbiol · 2021-10-27

该研究评估Vitek 2美罗培南-韦博巴坦(MEV)与参考肉汤微量稀释法(BMD)相比的性能。对449株肠杆菌目(按FDA/CLSI折点),总体必要一致性(EA)98.2%、分类一致性(CA)98.7%,无重大误差(VME/ME)。按EUCAST折点评估肠杆菌目和铜绿假单胞菌,总体EA 97.3%、CA 99.2%,VME 2.3%、ME 0.6%。

要点

  • Vitek 2 MEV对肠杆菌目(FDA/CLSI折点)EA 98.2%、CA 98.7%,无VME或ME。
  • 按EUCAST折点,铜绿假单胞菌EA 92.2%、CA 97.4%,VME 0%、ME 3.0%。
  • Vitek 2 MEV可作为MEV药敏的自动化替代方案。

核心结论

  • Vitek 2 MEV是用于肠杆菌目和铜绿假单胞菌MEV药敏的准确自动化系统,可作为参考BMD法的替代方案。

研究设计与样本

  • 多中心临床评估,比较Vitek 2 MEV与参考肉汤微量稀释法(BMD)。
  • 纳入449株肠杆菌目和438株FDA预期用途肠杆菌目,另评估铜绿假单胞菌(株数未报告)。

主要发现

  • 按FDA/CLSI折点,449株肠杆菌目总体EA 98.2%、CA 98.7%、VME 0%、ME 0%。
  • FDA预期用途的438株肠杆菌目EA 98.2%、CA 98.6%、VME 0%、ME 0%。
  • 按EUCAST折点,肠杆菌目和铜绿假单胞菌总体EA 97.3%、CA 99.2%、VME 2.3%、ME 0.6%(误差解决后EA 97.3%、CA 99.4%、VME 2.2%、ME 0.4%)。
  • 铜绿假单胞菌EA 92.2%、CA 97.4%、VME 0%、ME 3.0%(误差解决后EA 92.2%、CA 98.7%、VME 0%、ME 1.5%)。
  • 肠杆菌目(EUCAST)EA 98.2%、CA 99.6%、VME 3.0%、ME 0.2%。

关键数值与推荐

  • FDA/CLSI折点下肠杆菌目可评估EA为81.0%,仅基于42个在标可评估结果。
  • EUCAST折点下肠杆菌目和铜绿假单胞菌可评估EA为80.6%,仅基于67个可评估结果。

临床怎么用

  • Vitek 2 MEV可用于肠杆菌目和铜绿假单胞菌的MEV药敏测试,减少对人工BMD法的依赖。

局限性

  • 可评估EA基于少量在标结果(42和67个),可能影响准确性评估。
  • 按EUCAST折点评估时出现VME(总体2.3%,肠杆菌目3.0%),需关注误差解决后的性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The carbapenem/beta-lactamase inhibitor meropenem-vaborbactam (MEV) used to treat complicated urinary tract infections and pyelonephritis in adults was approved in 2017 by the U.S. Food and Drug Administration (FDA). Here, we evaluated Vitek 2 MEV (bioMérieux, Durham, NC) compared to the reference broth microdilution (BMD) method. Of 449 Enterobacterales isolates analyzed per FDA/CLSI breakpoints, the overall performance was 98.2% essential agreement (EA), 98.7% category agreement (CA), and 0% very major errors (VME) or major errors (ME). For 438 FDA intended-for-use Enterobacterales isolates, performance was 98.2% EA, 98.6% CA, and 0% VME or ME. Evaluable EA was 81.0%, but with only 42 on-scale evaluable results. Individual species demonstrated EA and CA rates of ≥90% without any VME or ME. When evaluated using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, overall Vitek 2 MEV performance for Enterobacterales and Pseudomonas aeruginosa demonstrated 97.3% EA, 99.2% CA, 2.3% VME, and 0.6% ME (after error resolution: 97.3% EA, 99.4% CA, 2.2% VME, and 0.4% ME) compared to the reference BMD method. Performance for P. aeruginosa included 92.2% EA, 97.4% CA, 0% VME, and 3.0% ME (after error resolution: 92.2% EA, 98.7% CA, 0% VME, and 1.5% ME). Performance for Enterobacterales included 98.2% EA, 99.6% CA, 3.0% VME, and 0.2% ME. Evaluable EA was 80.6% but was based on only 67 evaluable results. These findings support Vitek 2 MEV as an accurate automated system for MEV susceptibility testing of Enterobacterales and P. aeruginosa and could be an alternate solution to the manual-labor-intensive reference BMD method.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Dwivedi HP, Franklin S, Chandrasekaran S, et al. Multicenter Clinical Evaluation of Vitek 2 Meropenem-Vaborbactam for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa. J Clin Microbiol. 2021. PMID: 34705536. doi:10.1128/JCM.01610-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。